{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:53:38Z","timestamp":1793933618048,"version":"4.8.0"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Daily recombinant human GH (rhGH) is currently approved for use in children and adults with GH deficiency (GHD) in many countries with relatively few side-effects. Nevertheless, daily injections can be painful and distressing for some patients, often resulting in non-adherence and reduction of treatment outcomes. This has prompted the development of numerous long-acting GH (LAGH) analogs that allow for decreased injection frequency, ranging from weekly, bi-weekly to monthly. These LAGH analogs are attractive as they may theoretically offer increased patient acceptance, tolerability, and therapeutic flexibility. Conversely, there may also be pitfalls to these LAGH analogs, including an unphysiological GH profile and differing molecular structures that pose potential clinical issues in terms of dose initiation, therapeutic monitoring, incidence and duration of side-effects, and long-term safety. Furthermore, fluctuations of peak and trough serum GH and IGF-I levels and variations in therapeutic efficacy may depend on the technology used to prolong GH action. Previous studies of some LAGH analogs have demonstrated non-inferiority compared to daily rhGH in terms of increased growth velocity and improved body composition in children and adults with GHD, respectively, with no significant unanticipated adverse events. Currently, two LAGH analogs are marketed in Asia, one recently approved in the United States, another previously approved but not marketed in Europe, and several others proceeding through various stages of clinical development. Nevertheless, several practical questions still remain, including possible differences in dose initiation between na\u00efve and switch-over patients, methodology of dose adjustment\/s, timing of measuring serum IGF-I levels, safety, durability of efficacy and cost-effectiveness. Long-term surveillance of safety and efficacy of LAGH analogs are needed to answer these important questions.<\/jats:p>","DOI":"10.3389\/fendo.2021.637209","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T06:28:09Z","timestamp":1614148089000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":63,"title":["Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs"],"prefix":"10.3389","volume":"12","author":[{"given":"Kevin C. J.","family":"Yuen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar L.","family":"Boguszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0873","article-title":"Growth hormone safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults","volume":"174","author":"Allen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000452150","article-title":"Drug, Therapeutics C, Ethics Committee of the Pediatric Endocrine S. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency","volume":"86","author":"Grimberg","year":"2016","journal-title":"Horm Res Paediatr"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2016.11.005","article-title":"Treatment of growth hormone deficiency in children, adolescents and at the transitional age","volume":"30","author":"Richmond","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/cen.12691","article-title":"Three-year experience with access to nationally funded growth hormone (GH) replacement for GH-deficient adults","volume":"83","author":"Holdaway","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.pedn.2011.12.006","article-title":"Administration burden associated with recombinant human growth hormone treatment: perspectives of patients and caregivers","volume":"28","author":"Kremidas","year":"2013","journal-title":"J Pediatr Nurs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ghir.2016.04.006","article-title":"Early cessation and non-response are important and possibly related problems in growth hormone therapy: An OZGROW analysis","volume":"29","author":"Hughes","year":"2016","journal-title":"Growth Horm IGF Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13409","article-title":"Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial","volume":"87","author":"Battelino","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3776","article-title":"A randomized Phase 2 study of long-acting TransCon GH vs daily GH in childhood GH deficiency","volume":"102","author":"Chatelain","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.294","article-title":"Assessment of the pharmacokinetics, pharmacodynamics, and safety of single doses of TV-1106, a long-acting growth hormone, in healthy Japanese and Caucasian subjects","volume":"6","author":"Cohen-Barak","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0554","article-title":"Safety, pharmacokinetic and pharmacodynamic properties of TV-1106, a long-acting GH treatment for GH deficiency","volume":"173","author":"Cohen-Barak","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000470842","article-title":"Pharmacokinetic and pharmacodynamic modeling of MOD-4023, a long-acting human growth hormone, in growth hormone deficiency children","volume":"87","author":"Fisher","year":"2017","journal-title":"Horm Res Paediatr"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2017.12.002","article-title":"A first-in-man phase 1 trial for long-acting TransCon Growth Hormone","volume":"39","author":"Gilfoyle","year":"2018","journal-title":"Growth Horm IGF Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/DDDT.S93183","article-title":"Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children","volume":"10","author":"Hou","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1530\/EC-17-0007","article-title":"A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency","volume":"6","author":"Hoybye","year":"2017","journal-title":"Endocr Connect"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.414","article-title":"Pharmacokinetics, pharmacodynamics, and safety of a long-acting human growth hormone (MOD-4023) in healthy Japanese and Caucasian adults","volume":"7","author":"Kramer","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-16-0905","article-title":"Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies","volume":"177","author":"Luo","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0748","article-title":"MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults","volume":"176","author":"Strasburger","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-OR17-4","article-title":"TransCon growth hormone in the treatment of pediatric growth hormone deficiency: results of the Phase 3 heiGHt trial","volume":"3","author":"Thornton","year":"2019","journal-title":"J Endocrinol Soc"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0928","article-title":"Genentech Adult Growth Hormone Deficiency Study G. Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency","volume":"90","author":"Hoffman","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030825","article-title":"Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children","volume":"89","author":"Kemp","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2002.15.S2.715","article-title":"A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency","volume":"2","author":"Silverman","year":"15","journal-title":"J Pediatr Endocrinol Metab 2002"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-3279","article-title":"A randomized safety and efficacy study of somavaratan (VRS-317), a long-acting rhGH, in pediatric growth hormone deficiency","volume":"101","author":"Moore","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1437","article-title":"A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults","volume":"98","author":"Yuen","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.3.1222","article-title":"Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults","volume":"86","author":"Laursen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/BF00441309","article-title":"Final height and pubertal development in 55 children with idiopathic growth hormone deficiency, treated for between 2 and 15 years with human growth hormone","volume":"137","author":"Burns","year":"1981","journal-title":"Eur J Pediatr"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/acta.0.1040148","article-title":"Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children","volume":"104","author":"Kastrup","year":"1983","journal-title":"Acta Endocrinol (Copenh)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502231","article-title":"Diagnosis, genetics, and therapy of short stature in children: a Growth Hormone Research Society international perspective","volume":"92","author":"Collett-Solberg","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92328-3","article-title":"Beneficial effects of growth hormone treatment in GH-deficient adults","volume":"1","author":"Jorgensen","year":"1989","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198912283212605","article-title":"The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency","volume":"321","author":"Salomon","year":"1989","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.4.8636336","article-title":"Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers","volume":"81","author":"de Boer","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1997.3271123.x","article-title":"Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults","volume":"47","author":"Johannsson","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1993.tb02386.x","article-title":"Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters","volume":"39","author":"Moller","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.1.107","article-title":"The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults","volume":"83","author":"Cuneo","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.2.550","article-title":"Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women","volume":"82","author":"Burman","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.81.4.8636370","article-title":"The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender","volume":"81","author":"Johannsson","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1530\/EJE-07-0631","article-title":"Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia","volume":"157","author":"Ho","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0179","article-title":"Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Molitch","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4158\/GL-2019-0405","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care","volume":"25","author":"Yuen","year":"2019","journal-title":"Endocr Pract"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0111","article-title":"Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations","volume":"174","author":"Christiansen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nm0796-795","article-title":"A month-long effect from a single injection of microencapsulated human growth hormone","volume":"2","author":"Johnson","year":"1996","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2234","article-title":"Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD)","volume":"97","author":"Peter","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0216927","DOI":"10.1371\/journal.pone.0216927","article-title":"Long-term safety and effectiveness of growth hormone therapy in Korean children with growth disorders: 5-year results of LG Growth Study","volume":"14","author":"Rhie","year":"2019","journal-title":"PloS One"},{"key":"B43","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000489262","article-title":"Once-weekly administration of sustained-release growth hormone in Korean prepubertal children with idiopathic short stature: a randomized, controlled Phase II study","volume":"90","author":"Hwang","year":"2018","journal-title":"Horm Res Paediatr"},{"key":"B44","unstructured":"CHMP Safety Working Party\"s Response to the PDCO Regarding the Use of PEGylated Drug Products in the Paediatric Population"},{"key":"B45","unstructured":"CoxG\n          Long-acting Growth Hormone for Treating HIV-Associated Adipose Redistribution Syn.2008"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0536","article-title":"Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics","volume":"165","author":"de Schepper","year":"2011","journal-title":"Eur"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0422","article-title":"Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH","volume":"161","author":"Touraine","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1530\/EC-17-0203","article-title":"The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency","volume":"6","author":"Sprogoe","year":"2017","journal-title":"Endocr Connect"},{"key":"B49","unstructured":"Design and rationale for the height trial, a phase 3 transcon GH study in children with growth hormone deficiency\n            BeckertM\n            Brian KarpfD\n            MortensenE\n            MardellJ\n            ChristoffersenED\n            LeffJA\n          Orlando, FLEndocrine Reviews. Conference: 99th Annual Meeting of the Endocrine Society, ENDO 2017. United States. Vol 382017"},{"key":"B50","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ghir.2017.05.006","article-title":"Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone","volume":"35","author":"Thygesen","year":"2017","journal-title":"Growth Horm IGF Res"},{"key":"B51","first-page":"i1","article-title":"(NNC0195-0092) a Novel Long Acting Human GH Derivative Binds Tightly, but Reversibly to Albumin in Plasma","volume-title":"The Endocrine Society\u2019s 98th Annual Meeting and Expo, April 1\u20134, 2016","author":"Thygesen","year":"2016"},{"key":"B52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40262-018-0662-5","article-title":"Pharmacokinetics and pharmacodynamics of once-weekly Somapacitan in children and adults: supporting dosing rationales with a model-based analysis oftThree phase I trials","volume":"58","author":"Juul","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa614","article-title":"Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial","volume":"105","author":"Savendahl","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-1073","article-title":"Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial","volume":"178","author":"Johannsson","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14273","article-title":"Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone","volume":"93","author":"Otsuka","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa049","article-title":"Once-weekly Somapacitan is effective and well tolerated in adults with GH deficiency: a randomized phase 3 trial","volume":"105","author":"Johannsson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B57","first-page":"i1","article-title":"Preclinical Pharmacokinetic and Pharmacodynamic Studies of a Novel, Long Acting Growth Hormone (AG-B1512)","volume-title":"The Endocrine Society's 99th Annual Meeting and Expo, April 1-4, 2017","author":"Kim","year":"2017"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000449142","article-title":"Human Phase 1 Clinical Data of ALT-P1 (hGH-NexP) by Healthy Korean Males","volume":"86","author":"Lee","year":"2016","journal-title":"Horm Res Paediatr"},{"key":"B59","unstructured":""},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nm1610","article-title":"Ross RJ. A ligand-receptor fusion of growth hormone forms a dimer and is a potent long-acting agonist","volume":"13","author":"Wilkinson","year":"2007","journal-title":"Nat Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1039\/c3nr00474k","article-title":"Controlled release of human growth hormone fused with a human hybrid Fc fragment through a nanoporous polymer membrane","volume":"5","author":"Kim","year":"2013","journal-title":"Nanoscale"},{"key":"B62","first-page":"i1","article-title":"A Pharmacokinetic-Pharmacodynamic Analysis Of GX-H9, A Long-acting Hybrid Fc-fused Recombinant Human Growth Hormone (rhGH)","volume-title":"The Endocrine Society\u2019s 100th Annual Meeting and Expo, March 17-20, 2018","author":"Lee","year":"2018"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0185","article-title":"Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults","volume":"179","author":"Ku","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B64","first-page":"i1","article-title":"A Novel Long Acting Growth Hormone (HM10560A) Demonstrated Good Tolerability and Weekly Potential in Healthy Male Subjects after Single Administration","volume-title":"The Endocrine Society\u2019s 97th Annual Meeting and Expo, March 5-8, 2015","author":"Kang","year":"2015"},{"key":"B65","first-page":"i1","article-title":"6 Month Results of a Phase II, Randomized, Active Controlled, Open Label Study of Safety and Efficacy of HM10560A a Long Acting r-Hgh-HMC001 Conjugate in Adult Patients with Growth Hormone Deficiency (AGHD)","volume-title":"The Endocrine Society\u2019s 97th Annual Meeting and Expo, March 5-8, 2015","author":"Kang","year":"2015"},{"key":"B66","unstructured":"JCR Pharmaceuticals Development Pipeline"},{"key":"B67","unstructured":"JCR Announces Completion of Phase 1 Clinical Trial Notification of JR-142, A long-acting growth hormone"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-3547","article-title":"Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children","volume":"102","author":"Zelinska","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B69","unstructured":"Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency"},{"key":"B70","doi-asserted-by":"publisher","first-page":"dgz149","DOI":"10.1210\/clinem\/dgz149","article-title":"Long-acting growth hormone preparations - current status and future considerations","volume":"105","author":"Miller","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/adc.54.8.609","article-title":"Use of growth hormone-gel","volume":"54","author":"Lippe","year":"1979","journal-title":"Arch Dis Child"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0422-8","article-title":"Twelve-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency","volume":"16","author":"Biller","year":"2013","journal-title":"Pituitary"},{"key":"B73","unstructured":""},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2015.07.004","article-title":"Status of long-acting-growth hormone preparations\u20132015","volume":"25","author":"Hoybye","year":"2015","journal-title":"Growth Horm IGF Res"},{"key":"B75","unstructured":"McBrideR"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.12688\/f1000research.12057.1","article-title":"Update on GH therapy in adults","volume":"6","author":"Boguszewski","year":"2017","journal-title":"F1000Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa046.963","article-title":"Phase 3 fliGHt trial: experience of switching from daily growth hormone therapy to once-weekly TransCon HGH in children with growth hormone deficiency","volume":"4","author":"Maniatis","year":"2020","journal-title":"J Endocrinol Soc"},{"key":"B78","unstructured":""},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa046.1279","article-title":"Somatrogon growth hormone in the treatment of pediatric growth hormone deficiency: results of the pivotal pediatric Phase 3 clinical trial","volume":"4","author":"Deal","year":"2020","journal-title":"J Endocrinol Soc"},{"key":"B80","unstructured":""},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1702","article-title":"A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile","volume":"99","author":"Rasmussen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1991","article-title":"Reversible albumin-binding GH possesses a potential once-weekly treatment profile in adult growth hormone deficiency","volume":"101","author":"Rasmussen","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B83","unstructured":""},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09605-1","article-title":"Individual sensitivity to growth hormone replacement in adults","author":"Boguszewski","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1177\/039463200401700105","article-title":"Growth hormone antibodies formation in patients treated with recombinant human growth hormone","volume":"17","author":"Ahangari","year":"2004","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000497409","article-title":"Biological Significance of Anti-GH Antibodies in Children Treated with rhGH","volume":"91","author":"Binder","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-013-0059-8","article-title":"Long-acting growth hormone","volume":"15","author":"Hoybye","year":"2013","journal-title":"Paediatr Drugs"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0689","article-title":"Long-acting growth hormone for replacement therapy","volume":"96","author":"Johannsson","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2536","article-title":"Insulin and insulin-like growth factor signalling in neoplasia","volume":"8","author":"Pollak","year":"2008","journal-title":"Nat Rev Cancer"}],"updated-by":[{"DOI":"10.3389\/fendo.2021.705241","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000}}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.637209\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T13:52:59Z","timestamp":1624888379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.637209\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":89,"alternative-id":["10.3389\/fendo.2021.637209"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.637209","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fendo.2021.705241","asserted-by":"object"}]},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"article-number":"637209"}}